Search - tctmd.com

Displaying 401 - 420 of 646

Sort: Relevancy | Date

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Industry News

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Daily News

新型生物可吸收聚合物 SES 的良好结局持续 2 年

Yael L. Maxwell

October 02, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Industry News

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

September 14, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

Advertisement

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

DAPT Study Subanalysis Focuses on EES Subgroup

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Novel Devices Present New Treatment Options for STEMI

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

新型生物可吸收聚合物 SES 的良好结局持续 2 年

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content